Phoenix, ARIZONA3 Active Studies

Diffuse Large B-Cell Lymphoma Clinical Trials in Phoenix, ARIZONA

Find 3 actively recruiting diffuse large b-cell lymphoma clinical trials in Phoenix, ARIZONA. Connect with local research sites and explore new treatment options.

3
Active Trials
3
Sponsors
1,398
Enrolling

Recruiting Diffuse Large B-Cell Lymphoma Studies in Phoenix

About Diffuse Large B-Cell Lymphoma Clinical Trials in Phoenix

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for about 30% of cases. It is an aggressive lymphoma that grows rapidly. Treatment usually involves chemoimmunotherapy, with CAR-T cell therapy for relapsed cases.

There are currently 3 diffuse large b-cell lymphoma clinical trials recruiting participants in Phoenix, ARIZONA. These studies are seeking a combined 1,398 participants. Research is being sponsored by Celgene, Kite, A Gilead Company, Miltenyi Biomedicine GmbH. Clinical trial participation is free and participants receive study-related medical care at no cost.

Diffuse Large B-Cell Lymphoma Clinical Trials in Phoenix — FAQ

Are there diffuse large b-cell lymphoma clinical trials in Phoenix?

Yes, there are 3 diffuse large b-cell lymphoma clinical trials currently recruiting in Phoenix, ARIZONA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Phoenix?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you about next steps.

Are clinical trials in Phoenix free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Phoenix studies also compensate for your time and travel.

What diffuse large b-cell lymphoma treatments are being tested?

The 3 active trials in Phoenix are testing new therapies including novel drugs, biologics, and treatment approaches for diffuse large b-cell lymphoma.

Data updated March 2, 2026 from ClinicalTrials.gov